S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The World's First "$20 Trillion Drug (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
The World's First "$20 Trillion Drug (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The World's First "$20 Trillion Drug (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
The World's First "$20 Trillion Drug (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The World's First "$20 Trillion Drug (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
The World's First "$20 Trillion Drug (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
The World's First "$20 Trillion Drug (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
The World's First "$20 Trillion Drug (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
NASDAQ:ACOR

Acorda Therapeutics (ACOR) Stock Forecast, Price & News

$14.99
+0.47 (+3.24%)
(As of 09/29/2023 ET)
Compare
Today's Range
$14.05
$15.03
50-Day Range
$11.55
$17.60
52-Week Range
$5.60
$24.80
Volume
3,392 shs
Average Volume
7,949 shs
Market Capitalization
$18.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ACOR stock logo

About Acorda Therapeutics (NASDAQ:ACOR) Stock

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

ACOR Price History

ACOR Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
3 Biotech Stocks to Buy under $20
New Breakthrough "Living Software" Has Been…
New Breakthrough "Living Software" Has Been... Ukraine's "Secret Weapon" Against Russia The Washington Post Reports: "It's a big reason David is beating Goliath..." The Wall Street Journal Reports: "it's a technical revolution." Jeff Bezos Said: "It's in the realm of science fiction." Early investors can reap 5,633% gains on the small company revolutionizing warfare >>>
Q1 2023 Acorda Therapeutics Inc Earnings Call
8-K: Acorda Therapeutics, Inc.
Acorda Stock Gaps Up On Today's Open (ACOR)
See More Headlines
Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACOR
CUSIP
00484M10
Employees
111
Year Founded
1995

Profitability

Net Income
$-65,920,000.00
Pretax Margin
-18.02%

Debt

Sales & Book Value

Annual Sales
$118.57 million
Book Value
$77.13 per share

Miscellaneous

Free Float
1,210,000
Market Cap
$18.59 million
Optionable
Optionable
Beta
1.42

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Ron Cohen M.D. (Age 67)
    Founder, CEO, Pres & Director
    Comp: $984.15k
  • Mr. Michael A. Gesser M.B.A. (Age 60)
    Chief Financial Officer
    Comp: $459.15k
  • Mr. Kerry M. Clem (Age 53)
    Chief Commercial Officer
    Comp: $592.23k
  • Mr. Robert Morales (Age 55)
    Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller
  • Ms. Felicia Vonella
    VP of Investor Relations
  • Mr. Neil S. Belloff Esq. (Age 63)
    Gen. Counsel & Corp. Sec.
  • Ms. Tierney Saccavino
    Exec. VP of Corp. Communications
  • Ms. Denise J. Duca
    Exec. VP of HR
  • Mr. Andrew Mayer J.D.
    Sr. VP
  • Sofia Ali
    Sr. VP of Operations & Strategic Planning













ACOR Stock - Frequently Asked Questions

How have ACOR shares performed in 2023?

Acorda Therapeutics' stock was trading at $15.3340 at the start of the year. Since then, ACOR stock has decreased by 2.2% and is now trading at $14.99.
View the best growth stocks for 2023 here
.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 13,300 shares, an increase of 95.6% from the August 31st total of 6,800 shares. Based on an average daily trading volume, of 8,800 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.1% of the shares of the company are sold short.
View Acorda Therapeutics' Short Interest
.

When is Acorda Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ACOR earnings forecast
.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($7.55) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $29.68 million during the quarter. Acorda Therapeutics had a negative net margin of 17.89% and a negative trailing twelve-month return on equity of 26.63%.

When did Acorda Therapeutics' stock split?

Acorda Therapeutics shares reverse split on Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How do I buy shares of Acorda Therapeutics?

Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $14.99.

How much money does Acorda Therapeutics make?

Acorda Therapeutics (NASDAQ:ACOR) has a market capitalization of $18.59 million and generates $118.57 million in revenue each year. The biopharmaceutical company earns $-65,920,000.00 in net income (profit) each year or ($21.35) on an earnings per share basis.

How many employees does Acorda Therapeutics have?

The company employs 111 workers across the globe.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The official website for the company is www.acorda.com. The biopharmaceutical company can be reached via phone at (914) 347-4300 or via fax at 914-347-4560.

This page (NASDAQ:ACOR) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -